



## OPEN ACCESS

EDITED AND REVIEWED BY  
Margaret Hibbs,  
Monash University, Australia

\*CORRESPONDENCE  
Chang-Fu Kuo  
zandis@gmail.com

SPECIALTY SECTION  
This article was submitted to  
Autoimmune and Autoinflammatory  
Disorders: Autoimmune Disorders,  
a section of the journal  
Frontiers in Immunology

RECEIVED 26 July 2022  
ACCEPTED 08 August 2022  
PUBLISHED 29 August 2022

CITATION  
Huang Y-J, Lin C-H, Yang H-Y,  
Luo S-F and Kuo C-F (2022)  
Corrigendum: Urine soluble  
CD163 is a promising biomarker  
for the diagnosis and evaluation  
of lupus nephritis.  
*Front. Immunol.* 13:1003761.  
doi: 10.3389/fimmu.2022.1003761

COPYRIGHT  
© 2022 Huang, Lin, Yang, Luo and Kuo.  
This is an open-access article  
distributed under the terms of the  
[Creative Commons Attribution License  
\(CC BY\)](#). The use, distribution or  
reproduction in other forums is  
permitted, provided the original  
author(s) and the copyright owner(s)  
are credited and that the original  
publication in this journal is cited, in  
accordance with accepted academic  
practice. No use, distribution or  
reproduction is permitted which does  
not comply with these terms.

# Corrigendum: Urine soluble CD163 is a promising biomarker for the diagnosis and evaluation of lupus nephritis

Yun-Ju Huang<sup>1,2</sup>, Chiung-Hung Lin<sup>1,3</sup>, Huang-Yu Yang<sup>4</sup>,  
Shue-Fen Luo<sup>2</sup> and Chang-Fu Kuo<sup>1,2,5\*</sup>

<sup>1</sup>School of Medicine, Chang Gung University, Taoyuan City, Taiwan, <sup>2</sup>Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan City, Taiwan, <sup>3</sup>Division of Thoracic medicine, Chang Gung Memorial Hospital, Taoyuan City, Taiwan, <sup>4</sup>Division of Nephrology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan City, Taiwan, <sup>5</sup>Center for Artificial Intelligence in Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan

## KEYWORDS

Systemic lupus erythematosus, lupus nephritis, urine soluble CD163, urine biomarker, chronic kidney disease, macrophage, SLEDA

## A Corrigendum on

**Urine soluble CD163 is a promising biomarker for the diagnosis and evaluation of lupus nephritis**

by Huang Y-J, Lin C-H, Yang H-Y, Luo S-F and Kuo C-F (2022) *Front. Immunol.* 13:935700.  
doi: 10.3389/fimmu.2022.935700

In the published article, there was an error in **Figure 2** as published. We mistakenly used the **Figure 1** as **Figure 2**. The **Figure 1** describes us CD163 in urine and SLEDA4I-2K in SLE patients while the **Figure 2**




FIGURE 2

Correlation between usCD163/creatinine in urine and SLEDAI-2K in SLE patients. The renal SLE patients with high usCD163/creatinine ratios had higher SLEDAI-2K scores compared with those with low usCD163 levels. However, no difference in SLEDAI-2K score was seen between the inactive and extrarenal SLE patients. SLEDAI-2k, Systemic Lupus Erythematosus Disease Activity Index 2000.

describes usCD163/creatinine in urine and SLEDAI-2K in SLE patients. The corrected Figure 2 and its caption appear below.

In the published article, there was an error in the Funding statement. Funding from Chang Gung Memorial Hospital Research Program (CMRPG3J0031) was omitted. The correct Funding statement appears below.

## Funding

This study received funding from Key Development Project of Department of Science and Technology

(2015C03Bd051) and Chang Gung Memorial Hospital Research Program (CMRPG3J0031).

The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.